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PhagocytosisSynthetic microstructures can be engineered to deliver bioactive compounds impacting on their pharmacokinetics
and pharmacodynamics. Herein, we applied dextran-based layer-by-layer (LbL) microcapsules to deliver alpha-2-
macroglobulin (α2MG), a protein with modulatory properties in inflammation. Extending recent observations
madewith dextran-microcapsules loadedwithα2MG in experimental sepsis,we focusedon thephysical and chem-
ical characteristics of these microstructures and determined their biology on rodent and human cells. We report an
efficient encapsulation of α2MG into microcapsules, which enhanced i) human leukocyte recruitment to inflamed
endothelium and ii) humanmacrophage phagocytosis: in both settingsmicrocapsulesweremore effective than sol-
uble α2MG or empty microcapsules (devoid of active protein). Translation of these findings revealed that intrave-
nous administration of α2MG-microcapsules (but not empty microcapsules) promoted neutrophil migration into
peritoneal exudates and augmentedmacrophage phagocytic functions, the latter response being associatedwith al-
teration of bioactive lipidmediators as assessed bymass spectrometry. Thepresent study indicates thatmicroencap-
sulation can be an effective strategy to harness the complex biology of α2MG with enhancing outcomes on
fundamental processes of the innate immune response paving the way to potential future development in the con-
trol of sepsis.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
A promising method to provide controlled, sustained delivery
and release of proteins is the layer-by-layer (LbL) microencapsula-
tion technique [1]. Several studies have focused on the construction
of nano- and micro-capsules engineered as carriers for active
compounds including, enzymes, nucleic acids, proteins and chemo-
therapeutics. These protocols enact a drug-delivery system to carry
controlled quantities of a therapeutic payload to a specific target
site or tissue. Their main advantages are versatility, control
over function and response-tailored to capsule structure. Multi-
compartmental structure may allow inclusion of variousharmacology, William Harvey
Charterhouse Square, London
. This is an open access article undercompounds at defined doses in a single vesicle, altering their
activity and accessibility to environment [2–4]. Extensive research ofmi-
crocapsule (MC) delivery shows internalization by target cells
without overt toxicity. Microcapsules made of biodegradable polymers
can degrade over time to gradually release encapsulated compounds, a
phenomenon reported both in vivo and in vitro [5]. All these characteris-
tics make microcapsules a versatile delivery tool, amenable to the
delivery of proteins that can modulate the inflammatory process.
Most proteins have short half-lifewhen applied in vivo, requiringmul-
tiple administrations. Encapsulation often yields i) amelioration of
bioactions, ii) enhancement of therapeutic efficacy by delivery to a specif-
ic tissue and iii) delivery across biological barriers. Among the mediators
of the inflammatory process, the acute phase protein alpha-2-
macroglobulin (α2MG) is of particular interest. α2MG acts as a protease
inhibitor and carrier for several growth factors and cytokines, including
TNF-α, IL-1β, IL-6 and TGF-β [6]. Activation of α2MG results in the en-
trapment of proteases with the entire complex now being able to bind
to the low-density lipoprotein receptor like protein-1 (LRP-1; [7]), the
α2MG receptor. Therefore, the α2MG–LRP-1 pair has a great potentialthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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point in the pathogenesis of several diseases.
We have recently showed that α2MG is abundant in a specific sub-
set of neutrophil-derived vesicles (calledmicroparticles) [8], and to be a
major determinant for their protective effects in experimental sepsis
[9]. Soluble α2MG has a short systemic half-life in mice (~4 min) [10]
being mainly cleared by the liver [11]. To maximize α2MG protective
activity and study these effects in the absence of other proteins present
in the natural vesicles, we established if synthetic microcapsules could
recapitulate the biological functions ofα2MG. Biodegradablemicrocap-
sules were generated with a layer-by-layer microencapsulation
technique and loaded with α2MG. In a model of peritoneal sepsis the
synthetic α2MG-microcapsules controlled bacterial load, leading to
animal survival [9]. These initial experiments provided important
proof-of-concept that manufacturing microcapsules enriched with
α2MG was a viable strategy to replicate the bioactions of α2MG when
present in natural microvesicles. However, little is known about the
interaction and properties of the synthetic microcapsules with human
primary cells. Herein, we focused on the physical and chemical charac-
teristics of these new biodegradable microcapsules loaded with α2MG
and have investigated their interaction and biological functions in
human cells and experimental settings, revealing, for the first time,
their translational potential for therapeutic approaches.
2. Materials and methods
Please refer to the Supplementary Material for details on protocols,
materials and sources.Fig. 1. MC preparation and characterization. (A) MCs were generated using the layer-by-lay
sacrificial calcium carbonate template particles. (B) Morphology of α2MG-MCs (right panel)
(C) Flow-cytometer analysis; forward and side scatter plots (left andmiddle panels): MCs (gray
with the microcapsules. (D) Western Blot analysis of α2MG content in MCs in comparison wit2.1. α2MG enriched-microcapsule generation
Microcapsules (MCs) were prepared according to the LbL assembly
technique by alternate deposition of oppositely charged polyelectro-
lytes on sacrificial calcium carbonate template microparticles (see
Fig. 1 for schematic) [4]. α2MG was incorporated into the cores by co-
precipitation at the particle synthesis stage, as described [9]. As a con-
trol, an empty preparation of MCs was used. Positively charged PLA
and negatively charged DS were used for shell assembly and adsorbed
from 2 mg/ml solutions in 0.15 M NaCl. One middle layer of FITC–PLL
was adsorbed instead of PLA, used for the rest of positively charged
layers, to fluorescently label microcapsules for confocal visualization
and flow cytometry measurements. The final shell structure obtained
was PLA/DS/FITC–PLL/[DS/PLA]2 with a positively charged outermost
layer of PLA. After the shells were fully constructed, CaCO3 cores were
dissolved in 0.2 M EDTA (pH 6.5). To estimate the encapsulation effi-
ciency, supernatants were collected from particle synthesis, from the
first three layer depositions and particle dissolution steps (named A0,
A1, A2, A3, AE).
2.2. α2MG enriched-microcapsule characterization
Microcapsule morphology was characterized using FEI Inspect F
scanning electron and Leica TS confocalmicroscopes.MCswere counted
(obtaining values of 425 × 106 and 264 × 106 capsules/ml for α2MG-
and empty-MCs, respectively) and analyzed by flow cytometry with
BD LSRFortessa, together with 1 μm beads for comparison. The content
of α2MG was assessed by Western blot analysis in α2MG-MCs,er assembly protocol by alternate deposition of oppositely charged polyelectrolytes on
and empty-MCs (left panel) as shown by scanning electron and confocal microscopes.
cloud); 1 μmbeads (black cloud). Histograms (right panel): green fluorescence associated
h soluble protein.
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AE), loading soluble α2MG for comparison. To assess the efficiency of
encapsulation, un-loaded protein was quantified by inverted ELISA.
Standards (0.005–5 μg/ml of active α2MG) and supernatants A0, A1,
A2, A3 and AE were i) incubated overnight at 4 °C; ii) an anti-α2MG
(1:50,000; clone 2-M1 IIE7; BioMac) was applied for 2 h RT; iii) after
washing and incubation with anti‐mouse HRP-conjugated antibody
(1:5000; Invitrogen) for 2 h, 3,3′,5,5′-Tetramethylbenzidine (TMB) sub-
strate buffer (R&D System) was added for 30 min; iv) the reaction was
stopped with 1 N sulfuric acid (Sigma) and v) absorbance was read at
450 nmwith a fluorescence plate reader.
2.3. In vitro biological analyses
2.3.1. Preparation of human peripheral monocytes, monocyte-derived
macrophages (MDM) and neutrophils
Peripheral blood neutrophils andmonocyteswere freshly isolated as
described [12]. Purifiedmonocyte populationwas obtained by adhesion
(1 h, 37 °C, 5% CO2) and monocyte-derived macrophages (MDM) were
prepared from monocytes, by culture (8–10 days) in RPMI 1640 con-
taining 20% fetal bovine serum (FBS), glutamine and antibiotics [12].
2.3.2. Flow chamber assay
To assess leucocyte–endothelial interaction, primary human umbili-
cal vein endothelial cells (HUVEC) were collected and plated overnight
in μ-Slides VI0.4 (Ibidi™) [13,14]. The confluent monolayers were stim-
ulated with TNF-α (10 ng/ml) in complete medium (M199) 0% FBS
(to avoid contamination of exogenous α2MG), in the presence or ab-
sence of different amounts of MCs. Neutrophils were incubated for
10 min at 37 °C, and then perfused over endothelial cells at 1 dyn/cm2
for 8 min [14]. In another set of flow experiments, exogenous active
α2MG was applied (9.4 ng/slide).
2.3.3. Confocal microscopy
To visualize MCs and endothelial cell interaction, HUVEC and flown
neutrophils were stained with Alexa Fluor® 546-Phalloidin (5 U/ml,
Invitrogen) and left in Probing Antifade medium (Invitrogen) contain-
ing DAPI. They were visualized using a Zeiss LSM 510 META scanning
confocal microscope and analyzed by Zeiss LSM Imaging software
(Carl Zeiss). In another set of experiments, cells were stained with
Alexa Fluor® 633-Wheat germ agglutinin (1 μg/ml; Invitrogen) follow-
ed by anti-active α2MG antibody (10 μg/ml, clone 2-M1 IIE7, BioMac),
Alexa Fluor®594 secondary antibody (Invitrogen) and ProbingAntifade
medium (Invitrogen) containing DAPI. By acquiring Z-stack images, the
number of α2MG-positive particles on the membrane surface was
acquired and counted in each sample using NIH ImageJ 1.48 software.
2.3.4. Flow cytometry
Monocytes andMDMwere assessed for both surface and intracellu-
lar expression of α2MG receptor (LRP1 or CD91, 5 μg/ml, clone A2Mr
alpha-2, AbDSerotec) along with the lineage specific lineage marker:
CD14 (0.5 μg/ml, clone 61D3, eBioscence) for monocytes and CD68
(0.5 μg/ml, clone Y1/82A, eBioscence) for MDM. Cells were then ana-
lyzed with a FACSCalibur flow cytometer using CellQuest™ and FlowJo
software.
2.3.5. Phagocytosis assay
MDMwere evaluated for their ability to phagocytose Zymosan and
Escherichia coli (E. coli) particles. MDM were incubated with different
amounts of α2MG- or empty-MCs for 24 h (at 37 °C, 5% CO2). Zymosan
(Zymosan A from Saccharomyces cerevisiae) and E. coli particles (Strain
K12) were conjugated with a fluorescent dye (Bodipy® 576/589,
1 μM; Invitrogen). After 24 h of incubation with MCs, 125 μg/ml of fluo-
rescent Zymosan particles or 1mg/ml of fluorescent E. coli particles was
added to the medium for a further 20 min or 1 h, respectively (at 37 °C,
5% CO2). The number of fluorescent phagocytized particles wasdetermined with a fluorescence plate reader (BMG Labtech) and ana-
lyzed using MARS Data Analysis Software. Cells were further analyzed
by a scanning confocal microscope. To further corroborate our phagocy-
tosis results and discriminate between ingested and membrane-bound
particles, human macrophages were incubated with microcapsules
(1 × 105/well) or soluble α2MG (94 ng/well) as described above and
then incubated with phRodo E. coli (1 mg/ml, Invitrogen) for 30 min
(37 °C, 5% CO2), following the manufacturer's instructions. The fluores-
cent emission of internalized particles was analyzed by flow cytometry
(FACSCalibur using CellQuest™ and FlowJo software).
In another set of experiments Bodipy®-E. coli particle phagocytosis
was monitored in biogel-elicited mouse macrophages following the
same protocol above.
2.4. In vivo studies
C57Bl/6 mice (male, 6–8 weeks; Charles River) were used.
2.4.1. Acute peritonitis
Vehicle (PBS), empty MCs (1 × 105/mouse), α2MG-MCs (1 × 105/
mouse) or equivalent levels of soluble active α2MG (94 ng/mouse)
were administered i.v. followed by i.p. administration of Zymosan A
(0.1mg). Peritoneal lavages were collected after 4 h and leukocyte infil-
tration was assessed by light microscopy, followed by differential anal-
ysis using anti-Gr-1 and anti-F4/80 staining and flow cytometry
analysis.
2.4.2. In vivo phagocytosis
Mice were injected with 1 ml of 2% Bio-Gel (Bio-Rad) i.p. and 3 days
later, vehicle (PBS), empty MCs (1 × 106/mouse),α2MG-MCs (1 × 106/
mouse) or soluble α2MG (940 ng/mouse) was administered i.p. After
18 h, mice were injected with fluorescent- (Bodipy® 576/589, 1 μM;
Invitrogen) ZymosanA (1.6mg i.p.) and peritoneal lavageswere collect-
ed after 30 min. The fluorescence of engulfed particles in macrophages
was evaluated by flow cytometry.
2.4.3. Bioactive lipid quantification
Quantification of Protectin DX (PDX), Leukotriene B4 (LTB4), Prosta-
glandin E2 (PGE2), 5-Hydroxy Eicosatetraenoic acid (5-HETE), 15-
Hydroxy Eicosatetraenoic acid (15-HETE), 14-Hydroxy Docosahexaenoic
Acid (14-HDoHE), 17-Hydroxy Docosahexaenoic Acid (17-HDoHE), and
18-Hydroxy Eicosapentaenoic acid (18-HEPE) in peritoneal lavages, after
phagocytosis assay, was achieved by LC–MS/MS measurements as
described [15]. For each standard, calibration curves were built using
10 solutions at concentration ranging from 0.95 ng/ml to 500 ng/ml.
2.5. Statistical analysis
All statistical analyses were performed using GraphPad Prism (v6.0,
San Diego CA, USA). Data are expressed asmean± SEM of “n” indepen-
dent experiments. Statistical evaluation was performed by One-way
ANOVA with the Bonferroni post-test or unpaired Student's t-test
when appropriated. Differences were considered statistically significant
when p b 0.05.
3. Results
3.1. α2MG enriched-microcapsules and empty-microcapsules
Microcapsules were initially evaluated for their physicochemical
characteristics. Morphological analyses using scanning electron
(Fig. 1B upper panels) and confocal microscopes (Fig. 1B lower panels)
indicated typical spherical nature of the microstructures with some
folds likely created while drying. The sizes of individual capsules varied,
as expected [4]. Some aggregation of microcapsules could be observed
though not very pronounced. Comparing images from empty-MC and
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able morphological changes. Out of 6 distinct MC preparations using
0.5 or 1 mg α2MG for incorporation, a range of 160–425 × 106/ml and
264–375 × 106/ml α2MG-MCs and empty-MCs were produced (2 ml
of total solution for each preparation). Flow cytometry was performed
in relation to 1 μm beads, observing a diameter of ~ 1–2 μm (Fig. 1C),
with no specific difference in fluorescence intensity between empty
and α2MG-MCs (same units of fluorescence; Fig. 1C right panel).
To have a semi-quantitative and qualitative indication of α2MG in-
corporation in the capsules, Western blotting analysis was conducted.
Fig. 1D illustrates an exemplar one with different capsule loadings.
In general, 1 × 106 α2MG-MCs contained approximately 1 μg of
α2MG. Furthermore, the majority of α2MG was lost in the initial step
of incorporation as evident from detection in the A0 supernatant
(Fig. 1D; right blot). Quantitative data were obtained by ELISA: congru-
ently with the Western blotting data, only the A0 supernatant samples
contained α2MG. We could calculate approximately 6.4 μg of unloaded
protein, which is a minimal portion of the total amount of protein used
for encapsulation (800 μg), yielding a calculated encapsulation of 94 ng
of α2MG for 100,000 capsules. These microcapsules were tested in two
systemswhere natural vesicles enrichedwithα2MGdisplayed bioactiv-
ity [9].
3.2. Biological effects of microcapsules
First we tested α2MG-microcapsules and empty-microcapsules in
the flow chamber assay with human neutrophils and human umbilical
vein endothelial cells to corroborate the hypothesis that α2MG
entrapped in synthetic structure retained its ability to promote cell-to-
cell interaction. Thus, different amounts of α2MG-microcapsules,
or empty-microcapsules, were incubated with TNF-α-stimulatedFig. 2.MC interactionwith human endothelial monolayer. (A) Endothelial cells were treatedwi
1 × 105) before neutrophils flow (seeMaterials andmethods for protocol details). (B)MCs wer
different human donors forMC experiments, 3 for solubleα2MG (OnewayANOVA, Bonferroni
TNF-α and then vehicle (left panel), empty-MCs (central panel) andα2MG-MCs (right panel).
capsules are in green. (D) 3D images of α2MG-MC slide to demonstrate capsule insertion ontoendothelial cells for 4 h. Following flow at 1 dyn/cm2 of freshly isolated
human peripheral blood neutrophils, a good extent of white blood cell
adhesion was quantified with a significant effect of the capsules at
0.1 × 105 dose (51 ± 6, 36 ± 5 and 28 ± 3 adherent cells with
0.1 × 105 α2MG-microcapsules, empty-microcapsules or vehicle, re-
spectively; **p b 0.01). Fig. 2A illustrates the concentration–response
experiments, whereas Fig. 2B presents cumulative data for α2MG-
microcapsules, empty-microcapsules and soluble α2MG (added to an
equivalent amount of 9.4 ng). Confocal analyses of slides at the end of
the 8 min flow experiment displayed microcapsule interaction with
the human cells (Fig. 2C). Image reconstruction in Fig. 2D shows the
chiefly insertion of the microcapsules within endothelial cells (white
arrows). Collectively these results demonstrate that encapsulation tech-
nology ameliorates the pharmacological profile ofα2MG at least within
these experimental settings.
Next we wanted to visualize deposition of the protein on the human
cells. To this aim, neutrophils and endothelial monolayers were stained
with agglutinin alongwith a specific anti-α2MG antibody against the ac-
tive conformation of the protein. Fig. 3A reports these images. Wheat
germ-agglutinin recognizes sialic acid and N-acetylglucosaminyl resi-
dues on the plasma membrane, hence allowed us to analyze specifically
the surface of endothelial cells; herein, a significant deposition of α2MG
could be visualized (Fig. 3A). Two further notes are worthwhile. First,
basal immunostaining for α2MG was evident in control settings and
following incubation with empty microcapsules. Second, this was
not particularly different between the two conditions whereas signifi-
cant accumulation was quantified after α2MG-MCs (Fig. 3B). The
incremented α2MG-immunostaining is not solely associated with the
fluorescent capsules, indicating a potential release of the protein on the
endothelial cell surface, possibly providing opportunity to interact with
the recruited neutrophils.th TNF-α (10 ng/ml; 4 h) in the presence or absence of different amounts ofMCs (1 × 103–
e compared to an equivalent amount of solubleα2MG (9.4 ng). Data aremean± SEM of 9
post-test, **p b 0.01 vs. vehicle). (C) Confocal images of endothelialmonolayer treatedwith
Images show cells stained with Alexa Fluor® 546-Phalloidin (red) and DAPI (blue). Micro-
the endothelial monolayer (arrows). Images are representative of three distinct analyses.
Fig. 3.α2MG-microcapsules promote deposition of activeα2MG on the surface of human endothelial cells. (A) Confocal images of endothelial monolayers treated with TNF-α as in Fig. 2,
and then vehicle (upper panel), empty-MCs (central panel) orα2MG-MCs (bottom panel). Cells were stained with Alexa Fluor® 633-Wheat germ-agglutinin (gray), followed by anti-ac-
tiveα2MG antibody (red) andDAPI (blue). The intactmicrocapsules are in green. Z-stack imageswere acquired and the number ofα2MG-positive particles on the endothelialmembrane
surface was counted in each sample (right panel for each group, black spots). Images are representative of three distinct analyses. (B) Cumulative data forα2MG-positive particles as de-
termined by imaging software. Data are mean ± SEM of 3 independent experiments (Student's t test, *p b 0.05 vs. vehicle).
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phagocytosis. The putative α2MG receptor LRP1 is detected on
human neutrophils [9], thus we determined its expression on
human monocytes and monocyte-derived macrophages (MDM).
LRP-1 (CD91) is generally recognized as a receptor critical for
efferocytosis [16]. FACS analysis with an anti-CD91 antibody, along
with the lineage specific markers CD14 for monocytes and CD68 for
macrophages, revealed a predominant intracellular expression with
augmented overall expression in the latter cell type (Fig. 4A). Thus,
MDM were incubated for 24 h with α2MG-MCs or empty-MCs,
prior to the addition of two distinct phagocytic stimuli. As depicted
in Fig. 4B, incubation of MDMwith α2M-MCs significantly promotes
their ability to phagocytose Zymosan particles: this effect was
concentration-dependent at 1 × 105 and 0.3 × 105 α2MG-MCs. A
similar outcome was obtained with dead E. coli particles, though
higher increments over soluble α2MG could be calculated (e.g.
220 ± 20%, 134 ± 16% and 139 ± 11% increased phagocytosis over
vehicle for 1 × 105 α2M-MCs, 1 × 105 empty-MCs and 94 ng soluble
α2MG, respectively; Fig. 4C). These effects were not due to alteration
in cell viability as confirmed with human MDM (not shown) and
RAW 246.7 cells (Supplementary Fig. 1A). Moreover, using pH sensi-
tive E. coli particles we corroborated these results in human macro-
phages, demonstrating again a significantly increase of particleuptake in α2M-MC-treated cells as compared to empty capsules
and soluble protein treatments (N50%, *p b 0.05, Supplementary
Fig. 2). Capsules entered into human MDM cell cytoplasm, as seen
by confocal analysis, an effect independent from α2MG (Fig. 4D). In-
tact MCs could be detected even after the 24 h of incubation
(Fig. 4D). Interestingly, light microscopy imaging indicated that the
distribution of capsules was not homogenous among macrophages
with evidence for a subset of cells that internalized one or more cap-
sules, and others devoid of fluorescent material (Fig. 4E). This phe-
nomenon is not novel (as seen in RAW 246.7 cells with polystyrene
particles [17]) and it is more noticeable in low magnification (Sup-
plementary Fig. 3).
3.3. α2MG-MCs have protective effects on a model of peritonitis
In the final part of the study we queried whether α2MG-MCs could
be active during the complex and integrated settings of an inflammato-
ry reaction. To parallel the in vitro data, we focused on neutrophil re-
cruitment and macrophage phagocytosis. In a model of peritonitis,
intravenous administration of α2MG-MCs (selected dose of 1 × 105/
mouse) augmented the extent of neutrophil recruitment to the site of
inflammation: approximate +60–80% increment in cell numbers over
empty microcapsules or soluble α2MG (94 ng/mouse; Fig. 5A).
Fig. 4. α2MG-MCs promote monocyte-derived macrophage (MDM) uptake of Zymosan and E. coli particles. Expression of LRP1 on human monocytes and MDM as quantified by flow
cytometry in intact and permeabilized cells, along with CD14 for monocytes (0.5 μg/ml) and CD68 (0.5 μg/ml) for MDM. (A) Representative histograms showing augmented levels of
LRP1 expression on MDM; bar graphs show cumulative data (mean ± SEM, n = 4; One way ANOVA, Bonferroni post-test, **p b 0.01 vs.MDM surface expression). (B) MDM uptake of
fluorescent Zymosan (125 μg/ml, 20 min) or (C) E. coli (1 mg/ml, 1 h) particles upon MC application. Soluble α2MG (94 ng) was used for comparative purposes. Data are mean ± SEM
of 4 different human donors. Oneway ANOVA, Bonferroni post-test, **p b 0.01 vs. vehicle, +p b 0.05 vs. 1 × 105α2MG-MCs. (D) Representative confocal Z-stack images ofMDM incubated
with E. coli alone (vehicle) (left panel), α2MG-MCs and E. coli (central panel) or empty MCs and E. coli (right panel) as analyzed after phagocytosis. (E) Representative light microscopy
images of MDM after 24 h incubation with MCs (1 × 105 cells with 1 × 105 MCs).
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bers and not macrophage levels were affected by the α2MG-MC treat-
ment, as demonstrated by the use of cell-specific markers (Gr1 for
granulocytes and F4/80 for macrophages) (Fig. 5A). Next, α2MG-MCs
were tested for their ability to augment macrophage phagocytosis.
Thus, macrophages were elicited into the peritoneal cavity prior to
treatment i.p. with α2MG-microcapsules (1 × 106/mouse), empty-
microcapsules (1× 106/mouse), solubleα2MG (940ng/mouse) or vehi-
cle (PBS). The uptake of fluorescently labeled Zymosan A was assessed
18 h later, using a 30 min time point. Flow cytometry analysis allowed
quantification of the cells engulfed with fluorescent particles, as pre-
sented in Fig. 5B. Mice treated with α2MG-MCs displayed an increased
number of Zymosan+ve macrophages compared to the control group
(N70%, p b 0.01) and to soluble protein (N50%, p b 0.05). These results
were further corroborated in the ex-vivo setting with E. coli particles,
highlighting a critical different pharmacology as comparedwith the sol-
uble active protein (N30%, Supplementary Fig. 4).
Finally to establish downstreammechanisms potentially responsible
for the activating properties of α2MG-MCs on the acute inflammatory
response, metabololipidomics was performed on cell-free peritoneal la-
vages. As depicted in Fig. 6, mice treated with α2MG-MCs, in compari-
son to empty-MCs, displayed higher levels of the pro-inflammatory
chemoattractant LTB4, which derives from the lipoxygenation of arachi-
donic acid. The concentrations of the pro-resolving PDX were also aug-
mented post-treatment with α2MG-MCs as compared to empty-MCs.
Fig. 6A shows the chromatographic profiles for PDX, LTB4 and the
cyclo-oxygenase product PGE2, and their cumulative values: it can beseen that the effects were not univocal and, for instance, levels of PGE2
were not altered bymicrocapsule administration. Fig. 6B shows the typ-
ical fragmentation patterns for these exemplar mediators following
mass spectrometry. Moreover, the precursors for LXA4 and resolvins/
maresins were augmented upon administration of the α2MG-MCs
(Fig. 6C). Vehicle (PBS)-generatedmediators were comparable to levels
measured after treatment of mice with empty-MCs (not shown).
4. Discussion
We report here the generation of microcapsules loaded with α2MG
and describe their biological efficacy on themodulation of human endo-
thelial cell and macrophage reactivity. These analyses are completed
with proof-of-concept experiments in the mouse that reveal the ability
of α2MG – when delivered by the microcapsules – to incite the innate
immune response, amechanism that could underlie the reported effica-
cy in a model of sepsis [9]. Collectively these sets of experiments dem-
onstrated that α2MG-MCs retain immune-modulatory properties
during complex inflammatory settings, promoting neutrophil migration
during acute inflammation and augmenting the phagocytic properties
of macrophages.
Natural vesicles are emerging as a novel means for cell-to-cell
communication with potential impact in physiology as well as patholo-
gy, which would include valid use as biomarkers [20] and indeed ther-
apeutic tools [21]. However, these vesicles contain a large number of
proteins and other cargoes, e.g.microRNA and lipids, which could limit
their application or their efficacy over prolonged administration. For
Fig. 5.α2MG-MCs promote extravasation and phagocytosis within the peritoneal cavity. (A) Vehicle (PBS), empty MCs (1 × 105/mouse), α2MG-MCs (1 × 105/mouse) orα2MG (94 ng/
mouse)was administered i.v. followed by Zymosan A (0.1mg i.p.). Leukocyte infiltrationwas assessed in peritoneal lavages by differential flow cytometry using anti-Gr-1 and anti-F4/80.
Example of gate strategy for Gr-1+/F4 80− neutrophils is showed in the upper panel. Data are M ± SEM of 5 mice/group (*p b 0.05 vs. vehicle, +p b 0.05 vs. 1 × 105 α2MG-MCs).
(B) Vehicle, empty MCs and α2MG-MCs (1 × 106/mouse), or soluble active α2MG (940 ng/mouse) were injected i.p. into mice which had received 3 days earlier an injection of biogel.
After 18 h, fluorescent Zymosan A was injected and 30 min later the presence of engulfed particles in macrophages was evaluated by flow cytometry. Data report the percentage of
macrophages positive for Zymosan particles (exemplar plots are on the right hand side). Data are mean ± SEM of 4 mice/group (unpaired t-test, *p b 0.05, **p b 0.01 vs. α2MG-MCs).
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the vesicles would be detrimental for therapeutic development, even
more so if the antigenic protein(s) result to be one that is not pivotal
to the biological properties of interest. To this end, the exploding field
of nanomedicines could come in succor allowing encapsulation of spe-
cific bioactive molecules and ameliorate their targeting or pharmacoki-
netics, in all cases impacting on the pharmacodynamics (e.g. see recent
examples for an anti-inflammatory peptide [22,23]). Herein we focused
our attention ontoα2MG since we demonstrated i) the presence of this
protein in neutrophil-derived natural vesicles [8], ii) its segregated ex-
pression in vesicles quantified in patients surviving sepsis [9] and iii)
its ability tomodulatemouse cell reactivity, leading to partial protection
in experimental sepsis [9].
Efficient encapsulation of α2MG into microcapsules was achieved,
obtaining synthetic structures with the expected physical characteris-
tics of shape, size and stability. This extends α2MG to the list of biolog-
ically active tools that can be entrapped in these dextran-based
microstructures [5,24]. In line with recent studies, the efficiency of en-
capsulation was high with a limited loss of protein during the process,
calculated to be less than 1%. Encouraged by these results, then we test-
ed α2MG-MCs in experimental conditions using human cells central to
the immune response, these being endothelial cells and macrophages.
Crucial comparisons were made with empty MCs, prepared alongside
identical protocols, and/or soluble α2MG: our prediction was that
α2MG-MCs could harness α2MG biology with higher efficacy over thesoluble protein, presenting also specific biological properties when
compared to the empty microcapsules. In human umbilical vein endo-
thelial cells, α2MG-MCs led to increased adhesion of human neutro-
phils. This process is a hallmark of inflammation: neutrophils are the
first cell type to reach the site of injury and in order to do somust initial-
ly interactwith the vesselwall [25]. Using confocal studies,we could un-
veil an effective interaction and penetrance of the microcapsules into
the endothelium with consequent exposure of active α2MG. A back-
ground level ofα2MGwas detected onto themonolayer, even in the ab-
sence of the addition ofα2MG-MCs: this is plausibly due to thepresence
of the protein in the plasma added to the cell culture. In any case, we
predicted that the active protein presented on the surface of endothelial
cells would then interact with its receptor LRP1 presented by the rolling
neutrophil, promoting the subsequent step of adhesion. LRP1 was ini-
tially described as a ‘silent’ endocytic receptor [26], but evidence is
emerging that it can signal upon application of α2MG [27,28]. The
model that emerges is one where α2MG presented by the endothelial
monolayer activated the flowing neutrophil promoting the transition
from rolling to adhesion, thus committing to extravasation.
Meanwhile further studies are required to address the molecular
events evoked byα2MG engagement of LRP1 on the rolling neutrophil,
it is noteworthy that the model presented herein held consistency
in vivo. Intravenous injection of α2MG-microcapsules – at doses
coherent with what used in vitro when one considers an approximate
total blood volume of 3–5 ml in the mouse – augmented neutrophil
Fig. 6.α2MG-MCs increase pro-resolving lipid mediators. Mice were subjected to the phagocytic assay as in Fig. 5B. Lipids of interest were determined in peritoneal lavage by LC–MS/MS.
(A) Upper panel: Spectrum of relative peaks for Protectin DX, LTB4 and PGE2. Lower panel: LTB4, Protectin DX and PGE2 relative bar graphs. (B) Protectin DX, LTB4 and PGE2 signature
fragment ions reported asm/z, highlighting the diagnostic fragments. (C) 5-HETE, 15-HETE, 14-HDoHE, 17-HDoHE, and 18-HEPEwere identified and quantified by LC–MS/MS and divided
according to their downstream lipid product. Data are mean ± SEM of 4 mice/group (Student's t test, *p b 0.05 vs. empty-MCs).
291D.F. Canova et al. / Journal of Controlled Release 217 (2015) 284–292extravasation during on-going peritonitis. Such an effect would be ben-
eficial on theway the host could combat an infective status, as discussed
below. Intravenous injection of 1 × 105 capsules confirmed their inabil-
ity to cause toxicity (all animals survived). Furthermore, a specific ex-
periment was performed to localize the injected capsules in the liver,
spleen and lung. This was partially successful, since strong autofluores-
cence of the liver and spleen hampered easy detection of the capsules
(data not shown). In contrast, we could identify α2MG microcapsules
only in lung tissue sections by fluorescent microscopy (Supplementary
Fig. 5). However, we are confident that the capsules would have been
taken up by the liver and spleen, as demonstrated in a recent study
using capsules with similar chemical composition [29]. Next, we fo-
cused our attention onto the human macrophages, central to initiation
and resolution of the inflammatory response [30] and the main cell
type devoted to phagocytosis.
Initial works with similar microcapsules have demonstrated uptake
of the microstructures by immortalized macrophage cell lines, both
from human and murine origins [31] however studies with primary
cells are lacking. The addition of α2MG-microcapsules onto human
monocyte-derived macrophages resulted in a time-dependent uptake
(Supplementary Fig. 1B). At variance from the human endothelial
cells, macrophage uptake was optimal over a longer time-point, with
maximal result at 24 h incubation. However, this kinetics is similar to
that observed for the empty microcapsules and it is, therefore, a feature
of these microstructures and not secondary to the physical presence of
α2MG or one of its biological effect. Interestingly, only a subset of mac-
rophageswas shown to take up themicrocapsules. Thiswas a consistent
result with a proportion of cells engulfing well over one or two micro-
capsules and other adjacent cells being empty, with no microcapsules
at all. The molecular explanation of this dichotomy of response is
unclear however it is not uncommon and previously observed for
other phagocytic stimuli [17].Once inside the human macrophage, α2MG was in part released by
the microcapsules and consistently promoted phagocytosis of other
stimuli, as shownwith two unrelated particles of pathogenic relevance,
Zymosan A that is a major component of the yeast wall and the Gram
negative bacterium E. coli. In line with the kinetics of the phagocytosis
process (e.g. see our work with mouse macrophages and endogenous
Annexin A1 [32]), the engulfment of these pathogenic particles was
rapid with significant values within 30–45 min, yet augmented by pre-
vious uptake of the α2MG-MCs, as demonstrated by two experimental
approaches using different preparations of E. coli (Fig. 4C and Supple-
mentary Fig. 2). It is yet unknownhow theα2MG-MCswould accelerate
this response of the macrophage and this will require further studies.
The cytoplasmic domain of LRP1 contains the necessary structural fea-
tures to mediate phagocytosis [33]; it is unclear whether α2MG would
interact with LRP1 onto the phago-lysosome, inside the macrophage,
or if the protein is externalized to interact with LRP1 in a paracrine or
juxtacrine fashion.
The experimentswith humanmonocytes andMDMprovided anoth-
er interesting observation: LRP1 was present in the former though in-
creased expression was quantified upon differentiation in the latter,
reflecting the phagocytic role of macrophages [34]. We concluded this
set of experiments by reasoning again that it was important to establish
whether the positive modulation of macrophage phagocytosis could be
replicated in vivo. To this end, intraperitoneal injection of α2MG-MCs
promoted the uptake of fluorescent Zymosan and increased lipid
mediators' levels. The metabololipidomics revealed interesting mecha-
nistic connections. While the augmented level of LTB4 in α2MG-MC-
treated mice is in accordance with the enhanced extent of neutrophil
recruitment we showed in peritonitis, the elevation of PDX was of par-
ticular interest. This bioactive compound is produced via sequential
lipoxygenation of docosahexaenoic acid (22:6 n-3) and can be found to-
gether with the first identified protectin, protectin D1 (PD1) in mouse
292 D.F. Canova et al. / Journal of Controlled Release 217 (2015) 284–292inflammatory exudates [35]. Moreover, PDX and the other bioactive
tissue-protective mediators including the LXA4 and resolvins or
maresins are potent inducers of macrophage phagocytosis [36,37]. It is
of further interest that α2MG-MCs afforded significant modulation of
lipoxygenase dependent metabolism with little or no detectable effect
on the cyclo-oxygenase pathways.
Altogether these new results complement well the macroscopic
amelioration of experimental sepsis [9,38]. Our new data with human
cells and the mechanism revealed herein indicate that α2MG-MCs
could be developed for themanagement of human sepsis. From amech-
anistic perspective, efficacy in septic settings would derive from an aug-
mentation of neutrophil extravasation and macrophage phagocytosis,
cellular event of paramount importance in the way the host would
deal with the bacterial attack. A more general implication entails the
appreciation that synthetic microcapsules, filled with key players of
the inflammatory process, can harness their tissue-protective biology
by prolonging stability in the organism, and ultimately represent a
novel strategy for the delivery of therapeutics.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jconrel.2015.09.021.
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